HYPOPHOSPHATASIA
Clinical trials for HYPOPHOSPHATASIA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHOSPHATASIA trials appear
Sign up with your email to follow new studies for HYPOPHOSPHATASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare bone disease: phase 3 trial of ALXN1850 underway
Disease control OngoingThis study tests a new medicine called ALXN1850 for people aged 12 and older with hypophosphatasia (HPP), a rare bone disease. Participants receive either the drug or a placebo to see if it improves walking, strength, and daily function. The trial involves 124 people across multi…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
New hope for kids with rare bone disease as experimental drug enters final testing
Disease control OngoingThis study tests a new medicine called ALXN1850 in children aged 2 to 12 who have hypophosphatasia (HPP), a rare genetic condition that weakens bones. All participants have already been on the current treatment, asfotase alfa, for at least 6 months. The goal is to see if ALXN1850…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:35 UTC
-
Study to rescue Strensiq's power in hypophosphatasia patients
Disease control TerminatedThis study aimed to see if adding immunosuppressive therapy could help people with hypophosphatasia who stopped responding to the drug Strensiq due to their immune system. The study was withdrawn before enrolling any participants. It focused on patients who had antibodies against…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for kids with brittle bones: experimental drug shows promise
Disease control OngoingThis study tests a new medicine called ALXN1850 in children aged 2 to 12 with hypophosphatasia, a rare genetic condition that weakens bones. The goal is to see if the drug improves bone healing and movement compared to a placebo. About 30 children who have not received prior trea…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Scientists hunt for missing genes in rare bone disease
Knowledge-focused OngoingThis study aims to find hidden genetic changes in people with hypophosphatasia, a rare bone disease, who tested negative for known gene mutations. Researchers will also clarify whether certain uncertain gene variants actually cause the disease. About 66 participants will provide …
Matched conditions: HYPOPHOSPHATASIA
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated May 17, 2026 11:35 UTC